Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

Science. 1998 Oct 2;282(5386):103-7. doi: 10.1126/science.282.5386.103.

Abstract

To better understand the dynamics of hepatitis C virus and the antiviral effect of interferon-alpha-2b (IFN), viral decline in 23 patients during therapy was analyzed with a mathematical model. The analysis indicates that the major initial effect of IFN is to block virion production or release, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. The estimated virion half-life (t1/2) was, on average, 2.7 hours, with pretreatment production and clearance of 10(12) virions per day. The estimated infected cell death rate exhibited large interpatient variation (corresponding t1/2 = 1.7 to 70 days), was inversely correlated with baseline viral load, and was positively correlated with alanine aminotransferase levels. Fast death rates were predictive of virus being undetectable by polymerase chain reaction at 3 months. These findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alanine Transaminase / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Cell Death
  • Dose-Response Relationship, Drug
  • Half-Life
  • Hepacivirus / physiology*
  • Hepatitis C / immunology
  • Hepatitis C / therapy*
  • Hepatitis C / virology*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Kinetics
  • Models, Biological
  • RNA, Viral / blood
  • Recombinant Proteins
  • Regression Analysis
  • Viral Load
  • Viremia / virology
  • Virion / physiology
  • Virus Replication

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Alanine Transaminase